Pfizer vs Moderna: Which pharma stock has more upside?

They aren't just "pandemic stocks." ...

Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Should You Avoid Pfizer? Here's the Key Risk to Watch

Pfizer has reached a turning point.
InvestorsHub on MSN

Pfizer’s TALZENNA combination shows progress against prostate cancer

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income

Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating ...

Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?

The company incurred a loss in its most recent quarterly results.

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer. Here are some details: * Pfizer's ...
Las Vegas Sun

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
BioPharma Dive

Pfizer aims for wider use of PARP drug in prostate cancer with new data

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

Pfizer: I'm Still Expecting A Massive Rebound

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE at its earnings and acquisition.